IMMUNOHISTOCHEMISTRY, WT-1

The IHC – WT-1 (Wilms Tumor 1) test is an immunohistochemistry-based diagnostic assay used to detect WT-1 protein expression in tissue samples. WT-1 is a nuclear transcription factor that plays a critical role in the development of the kidneys, gonads, and mesothelial tissues. Because of its specific expression pattern, WT-1 is an important marker in surgical pathology and oncology.

This test is widely used to diagnose and classify ovarian serous carcinomas, Wilms tumor, mesothelioma, and certain renal and gynecological tumors. WT-1 staining helps pathologists identify the tissue origin of tumors and distinguish between different cancer subtypes that may appear similar under routine microscopic examination.

The IHC WT-1 test is especially valuable in differentiating primary ovarian serous carcinoma from metastatic adenocarcinomas and in confirming mesothelial differentiation in suspected mesothelioma cases.

Benefits of the Test

• Helps diagnose ovarian serous carcinoma
• Assists in identifying mesothelioma
• Supports classification of renal and gynecological tumors
• Helps determine tumor origin
• Improves diagnostic accuracy and treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC WT-1 test when evaluating ovarian tumors, renal tumors, mesothelioma, or cancers of uncertain origin. It is commonly used in:

• Ovarian serous carcinoma diagnosis
• Wilms tumor evaluation
• Malignant mesothelioma assessment
• Gynecological tumor classification
• Renal tumor investigations
• Metastatic cancer origin identification

WT-1 is frequently used alongside markers such as PAX8, CA125, Calretinin, Cytokeratin 7 (CK7), EMA, ER, and BerEP4 to provide a comprehensive tumor profile.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting is required
• No medication restrictions are generally necessary
• Clinical history, imaging findings, and pathology reports may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected ovarian cancer
• Individuals with suspected mesothelioma
• Patients with renal tumors requiring classification
• Cases requiring tumor origin identification
• Oncology patients requiring immunohistochemistry profiling

The IHC WT-1 test is an important diagnostic tool in gynecologic, renal, and thoracic pathology. By identifying WT-1 protein expression, it helps clinicians accurately diagnose tumors and develop appropriate treatment strategies.

Clinical Significance

WT-1 immunostaining is commonly used in the evaluation of:

• High-grade serous ovarian carcinoma
• Wilms tumor (nephroblastoma)
• Malignant mesothelioma
• Fallopian tube carcinoma
• Primary peritoneal serous carcinoma
• Selected renal tumors
• Gynecological malignancies

Strong nuclear WT-1 positivity is a characteristic finding in many ovarian serous carcinomas and mesothelial tumors.